On April 12, 2021 Kineta, Inc., a clinical stage biotechnology company focused on the development of novel immunotherapies in oncology, reported the presentation of new preclinical data on its VISTA antagonist antibody at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting 2021 (Press release, Kineta, APR 12, 2021, View Source;utm_medium=rss&utm_campaign=kineta-presents-new-preclinical-data-on-its-lead-vista-antagonist-antibody-at-the-aacr-annual-meeting-2021 [SID1234577896]). Thierry Guillaudeux, PhD, Senior Vice President Immuno-oncology at Kineta, presented a poster detailing new preclinical data on the company’s lead anti-VISTA antibody.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Key results with Kineta’s anti-VISTA lead antibody include the following:
Highly specific VISTA binding
Activates monocytes and this activation is NK cell dependent
Reverses MDSC suppression of T cells
Induces strong anti-tumor response as a single agent or in combo-therapies with anti-PD1 in different hard to treat tumor models
"Our lead anti-VISTA antibody has demonstrated exceptional preclinical performance which will enable Kineta to develop a differentiated immunotherapy with a new mechanism of action compared to the current T cell focus immunotherapies" said Shawn Iadonato, PhD, Chief Executive Officer at Kineta. "We are excited to advance IND enabling studies and enter the clinic in early 2022."
VISTA is a key driver of the immunosuppressive tumor microenvironment (TME) and is overexpressed on myeloid-derived suppressor cells (MDSC) and regulatory T cells (Tregs). It is a critical myeloid cell immune-checkpoint, and VISTA blockade can reprogram suppressive myeloid cells and reactivate antitumor immune function. Blocking VISTA activates an immune cell cascade that increases T cell effector functions to drive an efficient anti-tumor response. Preclinical studies have demonstrated single agent anti-VISTA activity but also demonstrate that targeting VISTA in combination with PD-1, PD-L1 or CTLA-4 can significantly improve the efficacy of those checkpoint inhibitors.
Presentation Details:
Title: A fully human anti-vista antibody as a promising therapy against poorly immunogenic tumors
Session Type: E-Poster Session
Session Title: Immune Checkpoints
Poster Number: 1637
Presenter: Thierry Guillaudeux, PhD
Click on the link below to take you to the Kineta website where you can view the presentation:
VISTA Publications – Kineta VISTA Presentation at AACR (Free AACR Whitepaper)